BIO is a curation and liquidity protocol for Decentralized Science (DeSci). Our mission is to accelerate biotechnology by giving global communities of patients, scientists and biotech professionals the ability to collectively fund, build and own tokenized biotech projects and intellectual property (IP).
The team behind BIO helped create Molecule, a tokenization platform for early-stage biomedicine, and VitaDAO, the largest decentralized community for longevity science. Building on these successes, BIO is designed to catalyze an onchain scientific economy through decentralized funding, incentives and liquidity.
The BIO token gives holders access to BIO's network of scientific communities and IP, enabling broad exposure to the DeSci economy.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for BIO. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: BIO is a Sell candidate.
BIO stock price ended at $0.045523 on 日曜日, after dropping 0.11%
On Jan 18, 2026 00:00, the price of BIO fell by 0.11%, dropping from $0.047014 to $0.045523 with 24h trading volume reaching $17.6M BIO.